ANTX

AN2 Therapeutics, Inc.

BS score 4.4LOWPHASE3 · mkt cap $109.6M · rev ttm $0

drug hypothesis

Epetraborole modulates Leucyl-tRNA synthetase (LeuRS) to treat Mycobacterium abscessus lung disease (non-tuberculous mycobacterial infection).

moa:Boron-containing antibiotic that inhibits bacterial leucyl-tRNA synthetase, disrupting protein synthesis in Mycobacterium abscessus

score breakdown

trial design0

base rate disconnect1

language red flags20

composite4.4

valuation analysis

market cap$109.6M

revenue ttm$0

phasePHASE3

historical base rate50%

disconnect ratio0.0x

lead trialNCT04892641

meta

cik0001880438

first discovered2026-04-09

last updated2026-04-10

statusACTIVE

llm model—

extracted at2026-04-10

trial design

Phase 2 randomized, quadruple placebo-controlled trial enrolling 84 patients with Mycobacterium abscessus lung disease. Primary assessment at Day 84 with multiple secondary endpoints including PGI-C, PGI-S, physician VAS, NTM Symptoms Scale, microbiological endpoints (sputum culture conversion, time to culture negativity), and safety monitoring for developing resistance.

primary endpoint:Clinical Response (NTM Symptom Evaluation Instrument) at Day 84

claimed differentiation

Unable to assess - no SEC filing content provided for business claims

language red flags

Unable to assess - no SEC filing content provided. Only clinical trial data available, which contains standard language without promotional claims.

company-stated risks

Unable to assess - no SEC filing content provided for risk disclosures

upcoming catalysts

2026-03Trial start enrollment
2027-07Primary completion